Skip to main content

Table 1 Baseline characteristics of the study population (n = 203) based on clinical diagnosis. Values are listed as the mean (± standard deviation) and dichotomous data as n (%)

From: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline

  Total population n = 203
Non-converted SCD SCD to MCI/AD p value
Characteristics n = 180 (89%) n = 23 (11%)  
Age, year 60 (±9) 67 (±8) < 0.001
Female 74 (41%) 14 (61%) 0.072
MMSE 28 (±1) 28 (±1) 0.036
APOE ε4 carrier (reported) 61 (34%) 16 (70%) <  0.001
ε4 homozygotes 51 (84%) 12 (75%)
ε4 heterozygotes 10 (16%) 4 (25%)
Follow-up duration, y 2.7 (±2.1)
Time to progression, y 2.5 (±2.2)
CSF Aβ42, pg/ml 1053 (±246) 800 (±203) <  0.001
Plasma Aβ40, pg/ml 208 (± 36) 203 (±34) 0.346
Plasma Aβ42, pg/ml 10 (±2) 9 (±2) 0.003
Plasma Aβ42/40 ratio 49 (±7) 44 (±7) 0.002
  1. Abbreviations: MCI mild cognitive impairment, MMSE Mini-Mental State Examination, SCD subjective cognitive decline